QuidelOrtho Corporation (QDEL) recently announced the FDA 510(k) clearance for its VITROS syphilis assay as part of its menu, which is likely to strengthen its position as a leader in infectious disease testing. The expansion into the U.S. market aims to provide timely and accurate diagnosis, crucial for effective treatment and control of the disease. With this latest development, QDEL's shares are likely to witness a northward movement. More on QDEL's VITROS Syphilis Assay The VITROS syphilis assay is desi ...